Loading...

NSPR INSPIREMD INC US FDA Inspections 8-K Filing

NSPR

NSPR

INSPIREMD INC

(NSPR)

2025 8-K

Show Summary

Summary

Financial Statements

Equity Offerings

New Product Launches

Pre-Market Approval

Pre-Market Approval

Financial Statements

Financial Results

Clinical Trial Update

Board Appointment

Earnings Announcement

New Headquarters

Inducement Plan

FDA Approval Application

Earnings Reports

Investor Presentation

Annual Meeting Voting Results

Equity Distribution Agreement

Earnings Reports

Amendment of Employment Agr...

Earnings Reports

CE Mark Recertification

Patent Issuance

Strategic Agreement

Earnings Reports

Clinical Trial Results

Reappointment of Officers

Earnings Reports

Completion of Enrollment in...

Investor Presentation

Earnings Reports

Securities Purchase Agreement

Earnings Reports

Promotion of Andrea Tommaso...

External Links:

On June 13, 2025, InspireMD, Inc. announced that they received CE Mark approval for their CGuard® Prime Embolic Prevention System under the European Medical Device Regulation, allowing them to market this product in Europe.

AI Assistant

INSPIREMD INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.